

27 March 2020

## Cordish Dixon Private Equity Fund III (ASX: CD3) COVID-19 Announcement

Walsh & Company Investments Limited (**Walsh & Company**), the Responsible Entity of Cordish Dixon Private Equity Fund III (**Fund**) has received a number of queries about the impact of the COVID-19 outbreak on the Fund. Walsh & Company continues to monitor the situation in relation to COVID-19 and is in contact with Cordish Private Ventures, LLC (**Cordish Private Ventures**) about the current situation in the United States (**US**) private equity market.

As with other global and US markets, we expect US private equity market conditions and transaction volumes will be impacted by the unprecedented change in business conditions, however, these impacts are not clear at this time. Walsh & Company, alongside Cordish Private Ventures, will continue to monitor the situation and will continue to keep unitholders informed of developments as information is released by the underlying fund managers which the Fund invests in through the limited partnership, US Select Private Opportunities Fund III, L.P.

Authorised for release by Walsh & Company Investments Limited (ACN 152 367 649, AFSL 410 433), the responsible entity of Cordish Dixon Private Equity Fund III.

The Cordish Dixon Private Equity Fund series comprise ASX listed and unlisted investment trusts focused on investing with and alongside leading, highly differentiated and specialised private equity funds focused on lower middle-market operating businesses in the US.